Multimodality Treatments in Metastatic Gastric Cancer
Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of spec...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (162 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545482304498 |
---|---|
ctrlnum |
(CKB)5400000000041993 (oapen)https://directory.doabooks.org/handle/20.500.12854/77077 (EXLCZ)995400000000041993 |
collection |
bib_alma |
record_format |
marc |
spelling |
Petrillo, Angelica edt Multimodality Treatments in Metastatic Gastric Cancer Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (162 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics. English Medicine bicssc advanced gastric cancer precision medicine new drug development gastro-oesophageal cancer mutational concordance exome sequencing formalin fixed paraffin embedded biomarkers gastric cancer metastatic body composition sarcopenia visceral fat area subcutaneous fat area outcome toxicity liver metastasis conversion surgery hepatectomy stage iv gastric cancer immune checkpoint inhibitors Epstein Barr Virus tumor mutational burden microsatellite instability predictive biomarkers CAR T cell therapy vaccines nutritional status metastatic gastric cancer target therapy bone flare stage IV treatment RANK-L liquid biopsy circulating tumor cell cfDNA ctDNA epithelial-mesenchymal transition resistance to treatment HER2-inhibition VEGFR-inhibition immunotherapy response monitoring 3-0365-2592-0 3-0365-2593-9 Petrillo, Angelica oth |
language |
English |
format |
eBook |
author2 |
Petrillo, Angelica |
author_facet |
Petrillo, Angelica |
author2_variant |
a p ap |
author2_role |
Sonstige |
title |
Multimodality Treatments in Metastatic Gastric Cancer |
spellingShingle |
Multimodality Treatments in Metastatic Gastric Cancer |
title_full |
Multimodality Treatments in Metastatic Gastric Cancer |
title_fullStr |
Multimodality Treatments in Metastatic Gastric Cancer |
title_full_unstemmed |
Multimodality Treatments in Metastatic Gastric Cancer |
title_auth |
Multimodality Treatments in Metastatic Gastric Cancer |
title_new |
Multimodality Treatments in Metastatic Gastric Cancer |
title_sort |
multimodality treatments in metastatic gastric cancer |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (162 p.) |
isbn |
3-0365-2592-0 3-0365-2593-9 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT petrilloangelica multimodalitytreatmentsinmetastaticgastriccancer |
status_str |
n |
ids_txt_mv |
(CKB)5400000000041993 (oapen)https://directory.doabooks.org/handle/20.500.12854/77077 (EXLCZ)995400000000041993 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Multimodality Treatments in Metastatic Gastric Cancer |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796651990763175936 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03729nam-a2200817z--4500</leader><controlfield tag="001">993545482304498</controlfield><controlfield tag="005">20231214133456.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/77077</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041993</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Petrillo, Angelica</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Multimodality Treatments in Metastatic Gastric Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (162 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">advanced gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">precision medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">new drug development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastro-oesophageal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutational concordance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">formalin fixed paraffin embedded</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">body composition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sarcopenia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">visceral fat area</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">subcutaneous fat area</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">toxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conversion surgery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stage iv gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Epstein Barr Virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor mutational burden</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microsatellite instability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR T cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nutritional status</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bone flare</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stage IV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RANK-L</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circulating tumor cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cfDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ctDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epithelial-mesenchymal transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance to treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HER2-inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VEGFR-inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">response monitoring</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2592-0</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2593-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Petrillo, Angelica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:55:07 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337927260004498&Force_direct=true</subfield><subfield code="Z">5337927260004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337927260004498</subfield></datafield></record></collection> |